Skip to main content
OpenTrials
Completed

NCT Number: NCT05027048

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity and mortality worldwide. Up to 80% of PPH is caused by uterine atony, the failure of the uterine smooth muscle to contract and compress the uterine vasculature after delivery. Laboratory and epidemiological studies show that low extracellular and serum calcium levels, respectively, decrease uterine contractility. A pilot study performed by the investigators supports the hypothesis that intravenous calcium chloride is well tolerated and may have utility in preventing uterine atony. The proposed research will establish the relationship between uterine tone and calcium through a clinical trial with an incorporated pharmacokinetic and pharmacodynamic (PK/PD) study. In a randomized, placebo-controlled, double-blind trial, investigators will establish the effect of 1 gram of intravenous calcium chloride upon quantitative blood loss and uterine tone during cesarean delivery in parturients with high risk of uterine atony. Investigators will concurrently collect serial venous blood samples to measure calcium for PK/PD modeling in this pregnant study cohort. High-quality clinical research and development of novel therapeutics to manage uterine atony are critical to reduce the high maternal morbidity and mortality from PPH.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient had a trial of labor for vaginal delivery prior to cesarean
  • Patient received an oxytocin infusion for labor augmentation or induction prior to cesarean

Exclusion criteria

  • renal dysfunction with serum Cr >1.0 mg/dL
  • known underlying cardiac condition
  • treatment with digoxin within the last 2 weeks for a maternal or fetal indication
  • treatment with a calcium channel blocker medication within 24 hours
  • hypertension necessitating intravenous antihypertensive medication within 24 hours
  • emergent case in which study participation could in any way impede patient care by the judgement of the obstetrician, anesthesiologist, or bedside nurse

Treatment and study plan

Calcium chloride

Drug

See arm description above

Saline placebo

Drug

see arm description above

Primary outcomes

  1. Quantitative Blood Loss

    Time frame: measurement occurs at conclusion of operating room case

    Standardized volumetric and gravimetric assessment of blood loss during cesarean. Note: will analyze all participants, but planned subgroup analysis will also occur excluding patients with non-atonic reasons for blood loss including hysterotomy extension, placental abruption, cervical or vaginal laceration, etc

Secondary outcomes

  1. Number of Participants With Postpartum Hemorrhage

    Time frame: operative course (within 4-6 hours of fetal delivery)

    Postpartum hemorrhage was defined as quantitative blood loss > 1000 milliliters during operative course

  2. Number of Participants With Second Line Uterotonic Requirement

    Time frame: within 4 hours of delivery

    Yes/no: did the patient require treatment with methylergonovine, carboprost, and/or misoprostol for uterine atony

  3. Number of Patients With a Transfusion Requirement

    Time frame: 96 hours of delivery

    Yes/no, if patient required transfusion of packed red blood cells prior to hospital discharge

  4. Change in Hematocrit From Baseline

    Time frame: 1 day

    Measured pre-delivery hematocrit minus measured post-operative day 1 hematocrit. Correction factor of 3 hematocrit points per unit packed red blood cells transfused

  5. Total Oxytocin Bolus Requirement

    Time frame: Cesarean duration, within 4-6 hours of fetal delivery

    Total dose oxytocin bolus during cesarean

  6. Uterine Tone Numerical Rating Score, 7 Minutes After Fetal Delivery

    Time frame: 7 minutes after fetal delivery, 5 minutes after initiating study drug infusion

    Uterine tone assessment: Obstetricians at the study institution use the following validated scale to grade uterine tone for all cesarean deliveries. The obstetrician places their hand directly on the uterine fundus and scores the adequacy of contraction. The interrater characteristics of this scale have been published (Cole et al, 2021).

    The scale ranges from 0-10. A score of 0 is the worst possible score and represents a flaccid, atonic uterus. A score of 10 is the best possible score and represents a firmly-contracted uterus.

  7. Uterine Tone Numerical Rating Score, 12 Minutes After Fetal Delivery

    Time frame: 12 minutes after fetal delivery, 10 minutes after initiating study drug infusion

    Uterine tone assessment: Obstetricians at the study institution use the following validated scale to grade uterine tone for all cesarean deliveries. The obstetrician places their hand directly on the uterine fundus and scores the adequacy of contraction. The interrater characteristics of this scale have been published (Cole et al, PMID 33652161).

    The scale ranges from 0-10. A score of 0 is the worst possible score and represents a flaccid, atonic uterus. A score of 10 is the best possible score and represents a firmly-contracted uterus.

  8. Fluid Requirement

    Time frame: Operating room duration, usually 2 hours

    Total crystalloid required during cesarean delivery in mL

  9. Percent Change in Mean Arterial Pressure

    Time frame: every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline

    Baseline mean arterial blood pressure recorded as average of first 6 mean arterial blood pressures recorded in operating room. Percent change calculated as measured mean arterial blood pressure minus baseline, divided by baseline. Reported here as the maximal decrease in mean arterial pressure. Repeated measures ANOVA reported in Statistical Analysis.

  10. Percent Change in Heart Rate From Baseline

    Time frame: every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline

    Baseline heart rate recorded as average of first 6 heart rates recorded in operating room. Percent change calculated as measured heart rate minus baseline, divided by baseline. Maximal % increase in heart rate reported here. Repeated measures ANOVA used to analyze overall trend in Statistical Analysis below.

  11. Total Phenylephrine Requirement

    Time frame: Duration of operating room time, up to 240 minutes

    Total phenylephrine in milligrams administered while in the operating room

  12. Pharmacokinetics of Calcium Chloride - Baseline Ionized Calcium

    Time frame: In the operating room prior to study drug administration (generally <30 minutes prior to fetal delivery and study drug administration)

    Measured using an Abbott istat machine and CG8+ cartridge to determine venous blood gas ionized calcium levels

  13. Pharmacokinetics of Calcium Chloride - Peak Change in Ionized Calcium From 1 Gram of Calcium Chloride

    Time frame: At Tmax (conclusion of the 10-minute intravenous calcium chloride infusion

    Generated from a 2-compartment population pharmacokinetic model in NONMEM using serial venous blood gas ionized calcium concentrations.

  14. Pharmacodynamic Effect of Calcium Upon Uterine Tone NRS

    Time frame: Within 20 minutes of study drug administration

    Data were not collected. This measure required blood specimens to be obtained at the time of tone scores and this was not done.

Other outcomes

  1. Quantitative Blood Loss, Subgroup Quantitative Blood Loss (QBL, mL), Excluding Cases of Documented Non-atonic Bleeding

    Time frame: Calculated at conclusion of operating room case

    Pre-specified subgroup analysis of primary outcome:

    Because the proposed mechanism of calcium action-improving uterine contractility-was not expected to improve bleeding from causes such as hysterotomy extension or arterial bleeding, the trial was powered for a prespecified subgroup analysis excluding patients with nonatonic blood loss documented in the surgeon's operative report. Documented nonatonic bleeding was defined as presence in the surgeon's operative report narrative of any of the following: hysterotomy extension, hysterotomy types other than low transverse (eg classical, T- or J-shaped), invasive or abnormally adherent placenta, placental abruption, uterine rupture, bleeding from leiomyomas, grade 3 or 4 vaginal lacerations, or cervical lacerations.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Collaborators

  • Foundation for Anesthesia Education and Research
  • Society for Obstetric Anesthesia and Perinatology

Registry information

Official study title

Calcium Chloride for Prevention of Blood Loss From Uterine Atony During Intrapartum Cesarean Delivery (CALBLOC): a Double Blind, Randomized, Placebo Controlled Trial and Nested Population Pharmacokinetic and Pharmacodynamic Analysis

Acronym: CALBLOC

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 30, 2021
Registry last updated
Jun 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.